Thursday, September 8, 2011

NeurogesX seeks to expand pain patch use

NeurogesX Inc. wants to expand the market of its Qutenza pain patch to include people with HIV-associated nerve pain.
The San Mateo company (NASDAQ: NGSX) said Thursday that it filed a supplemental new drug application with the Food and Drug Administration. The application includes a request for priority review, which would cut the agency’s review time from 10 months to six months.

No comments:

Post a Comment